Interindividual Regulation of the Breast Cancer Resistance Protein/ABCG2 Transporter in Term Human Placentas
Authors:
- Kristin M. BircsakKBKristin M. Bircsak
- Jamie E. MoscovitzJMJamie E. Moscovitz
- Xia WenXWXia Wen
- Faith ArcherFAFaith Archer
- Poi Yu Sofia YuenPYPoi Yu Sofia Yuen
- Moiz MohammedMMMoiz Mohammed
- Naureen MemonNMNaureen Memon
- Barry I. WeinbergerBWBarry I. Weinberger
- Laura M. SabaLSLaura M. Saba
- Anna M. VetranoAVAnna M. Vetrano
- Lauren M. AleksunesLALauren M. Aleksunes
- 1 May 2018
- journal article
- research article
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 46 (5) , 619-627
Abstract
The breast cancer resistance protein (BCRP/ABCG2) is a maternally-facing efflux transporter that regulates the placental disposition of chemicals. Transcription factors and gene variants are important regulatory factors that influence transporter expression. In this study, we sought to identify the genetic and transcriptional mechanisms underlying the interindividual expression of BCRP mRNA and protein across 137 term placentas from uncomplicated pregnancies. Placental expression of BCRP and regulatory transcription factor mRNAs was measured using multiplex-branched DNA analysis. BCRP expression and ABCG2 genotypes were determined using Western blot and Fluidigm Biomark genetic analysis, respectively. Placentas were obtained from a racially and ethnically diverse population, including Caucasian (33%), African American (14%), Asian (14%), Hispanic (15%), and mixed (16%) backgrounds, as well as unknown origins (7%). Between placentas, BCRP mRNA and protein varied up to 47-fold and 14-fold, respectively. In particular, BCRP mRNA correlated significantly with known transcription factor mRNAs, including nuclear factor erythroid 2-related factor 2 and aryl hydrocarbon receptor. Somewhat surprisingly, single-nucleotide polymorphisms (SNPs) in the ABCG2 noncoding regions were not associated with variation in placental BCRP mRNA or protein. Instead, the coding region polymorphism (C421A/Q141K) corresponded with 40%–50% lower BCRP protein in 421C/A and 421A/A placentas compared with wild types (421C/C). Although BCRP protein and mRNA expression weakly correlated (r = 0.25, P = 0.040), this relationship was absent in individuals expressing the C421A variant allele. Study results contribute to our understanding of the interindividual regulation of BCRP expression in term placentas and may help to identify infants at risk for increased fetal exposure to chemicals due to low expression of this efflux protein.Keywords
This publication has 42 references indexed in Scilit:
- Association between DNA Methylation in the miR-328 5’-Flanking Region and Inter-individual Differences in miR-328 and BCRP Expression in Human PlacentaPLOS ONE, 2013
- A novel xenobiotic responsive element regulated by aryl hydrocarbon receptor is involved in the induction of BCRP/ABCG2 in LS174T cellsBiochemical Pharmacology, 2010
- Expression of ABCG2 (BCRP) Is Regulated by Nrf2 in Cancer Cells That Confers Side Population and Chemoresistance PhenotypeMolecular Cancer Therapeutics, 2010
- Multistrip Western Blotting to Increase Quantitative Data Output2009
- Expression of the breast cancer resistance protein (Bcrp1/Abcg2) in tissues from pregnant mice: effects of pregnancy and correlations with nuclear receptorsAmerican Journal of Physiology-Endocrinology and Metabolism, 2006
- Expression of breast cancer resistance protein (BCRP/ABCG2) in human placenta throughout gestation and at term before and after laborCanadian Journal of Physiology and Pharmacology, 2006
- PPARγ, a Lipid‐Activated Transcription Factor as a Regulator of Dendritic Cell FunctionAnnals of the New York Academy of Sciences, 2006
- Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pumpBlood, 2004
- Phytoestrogens/Flavonoids Reverse Breast Cancer Resistance Protein/ABCG2-Mediated Multidrug ResistanceCancer Research, 2004
- Identification of a Novel Estrogen Response Element in the Breast Cancer Resistance Protein ( ABCG2 ) GeneCancer Research, 2004